Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

NACompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Pain, Postoperative
Interventions
GENETIC

CYP2D6-guided opioid therapy

Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.

Trial Locations (3)

32610

UF Health at the University of Florida, Gainesville

32611

Unversity of Florida, Gainesville

34491

UF Health Orthopaedic--Villages, Summerfield

All Listed Sponsors
collaborator

University of Florida Health

OTHER

lead

University of Florida

OTHER

NCT03534063 - Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery | Biotech Hunter | Biotech Hunter